Literature DB >> 14518572

Lipid-lowering: can ezetimibe help close the treatment gap?

Ryan C Neal1, Peter H Jones.   

Abstract

Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14518572     DOI: 10.3949/ccjm.70.9.777

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  3 in total

1.  LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.

Authors:  James McKenney; Christie M Ballantyne; Theodore A Feldman; William E Brady; Arvind Shah; Michael J Davies; Joanne Palmisano; Yale B Mitchel
Journal:  MedGenMed       Date:  2005-07-14

2.  Burkholderia cenocepacia: a new biocatalyst for efficient bioreduction of ezetimibe intermediate.

Authors:  Amit Singh; Abdul Basit; Uttam C Banerjee
Journal:  J Ind Microbiol Biotechnol       Date:  2009-08-08       Impact factor: 3.346

Review 3.  Combination therapy in cholesterol reduction: focus on ezetimibe and statins.

Authors:  Liliana Grigore; Giuseppe Danilo Norata; Alberico L Catapano
Journal:  Vasc Health Risk Manag       Date:  2008
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.